Metraipolis › archive › dc_66cfb226e95c

Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus… — Europe PMC PMID:32130229

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/32130229
DOI
10.1371/journal.pone.0228163
License (as archived)
CC0-1.0
Archived
2026-11-09T07:55:21.073Z
SHA-256 of the archived text
b048c61ce268a87c86d79853baae8b2d847440e3026af54187f53ba15b7e6b9c
Stable URL of this page
https://metraipolis.com/documento/dc_66cfb226e95c

How to cite

Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus… — Europe PMC PMID:32130229 — Europe PMC (en), https://europepmc.org/article/MED/32130229 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_66cfb226e95c (Metraipolis archive dc_66cfb226e95c, sha256 b048c61ce268a87c86d79853baae8b2d847440e3026af54187f53ba15b7e6b9c)
BibTeX
@misc{dc66cfb226e95c,
  title = {Immunotherapy with DNA vaccine and live attenuated rubella/SIV gag vectors plus early ART can prevent SIVmac251 viral rebound in acutely infected rhesus… — Europe PMC PMID:32130229},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32130229},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_66cfb226e95c; sha256 b048c61ce268a87c86d79853baae8b2d847440e3026af54187f53ba15b7e6b9c},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32130229. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Anti-retroviral therapy (ART) has been highly successful in controlling HIV replication, reducing viral burden, and preventing both progression to AIDS and viral transmission. Yet, ART alone cannot cure the infection. Even after years of successful therapy, ART withdrawal leads inevitably to viral rebound within a few weeks or months. Our hypothesis: effective therapy must control both the replicating virus pool and the reactivatable latent viral reservoir. To do this, we have combined ART and immunotherapy to attack both viral pools simultaneously. The vaccine regimen consisted of DNA vaccine expressing SIV Gag, followed by a boost with live attenuated rubella/gag vectors. The vectors grow well in rhesus macaques, and they are potent immunogens when used in a prime and boost strategy. We infected rhesus macaques by high dose mucosal challenge with virulent SIVmac251 and waited three days to allow viral dissemination and establishment of a reactivatable viral reservoir before starting ART. While on ART, the control group received control DNA and empty rubella vaccine, while the immunotherapy group received DNA/gag prime, followed by boosts with rubella vectors expressing SIV gag over 27 weeks. Both groups had a vaccine "take" to rubella, and the vaccine group developed antibodies and T cells specific for Gag. Five weeks after the last immunization, we stopped ART and monitored virus rebound. All four control animals eventually had a viral rebound, and two were euthanized for AIDS. One control macaque did not rebound until 2 years after ART release. In contrast, there was only one viral rebound in the vaccine group. Three out of four vaccinees had no viral rebound, even after CD8 depletion, and they remain in drug-free viral remission more than 2.5 years later. The strategy of early ART combined with immunotherapy can produce a sustained SIV remission in macaques and may be relevant for immunotherapy of HIV in humans.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2020 (prima pubblicazione 2020-03-04).
Identificativi: PMID 32130229 · PMCID PMC7055890 · DOI 10.1371/journal.pone.0228163.
Pagina: https://europepmc.org/article/MED/32130229 — https://doi.org/10.1371/journal.pone.0228163. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-09T07:49:11.411Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.